{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-24-000086","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.117927+00:00","generated_at":"2026-05-31T09:44:54.956395+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Praxis reports Q2 2024 net loss $32.7M; cash $433.8M; multiple trial milestones on track","bullets":["Cash and investments $433.8M ($81.3M at Dec 31, 2023); runway into 2027.","Net loss $32.7M vs $34.3M YoY; R&D expense $27.3M vs $25.6M.","Ulixacaltamide Essential3 interim analysis in Q4 2024; NDA submission on track for 2025.","Relutrigine (PRAX-562) Phase 2 EMBOLD topline results expected Q3 2024.","PRAX-628 Phase 2/3 POWER1 study to start Q4 2024; RADIANT Phase 2 topline H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-24-000086","json":"https://secwatch.observer/filing/0001689548-24-000086.json","markdown":"https://secwatch.observer/filing/0001689548-24-000086.md","text":"https://secwatch.observer/filing/0001689548-24-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000086/0001689548-24-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000086/prax-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:54.956395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}